Cellular and molecular neurosurgery: Pathways from concept to reality .1. Target disorders and concept approaches to gene therapy of the central nervous system

被引:84
作者
Zlokovic, BV
Apuzzo, MLJ
机构
[1] UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT NEUROL SURG,LOS ANGELES,CA
[2] UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV NEUROSURG,LOS ANGELES,CA
关键词
Alzheimer's disease; brain tumor; gene therapy; molecular genetics; molecular neurosurgery; Parkinson's disease; stroke; FAMILIAL ALZHEIMERS-DISEASE; THYMIDINE KINASE GENE; MALIGNANT BRAIN-TUMORS; PLASMINOGEN-ACTIVATOR; RETROVIRAL VECTORS; APOLIPOPROTEIN-E; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-2; IMMUNE SURVEILLANCE; MISSENSE MUTATIONS;
D O I
10.1097/00006123-199704000-00027
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
RECENT ADVANCES IN cellular and molecular biology and better understanding of genetic and biochemical bases of different central nervous system (CNS) disorders have made gene therapy of the CNS a realistic goal. Concept approaches for gene therapy of CNS disorders are reviewed and include the following: 1) gene replacement with a single normal allele to correct the inherited global neurodegenerative disorders, such as enzyme deficiencies; 2) brain repair to restore the function of a particular subset of cells that were lost because of a neurodegenerative process; 3) gene therapy of brain tumors; and 4) gene therapy of stroke. Techniques of viral vector-mediated CNS transfer of a therapeutic gene, transplantation of genetically modified cells, fetal embryonic implantation and/or implantation of genetically engineered neural progenitor cells, and production of a specific enzyme, neurotransmitter, and/or growth factor are discussed with respect to the therapeutic potential for global and localized CNS neurodegenerative disorders and stroke. Transfection of the CNS tumor cells with the drug susceptibility (''suicide'') gene and/or ''toxic'' gene and antisense strategies and a concept of adoptive immunotherapy of brain tumors are also discussed. Other approaches, such as transfer of drug-resistant genes and monoclonal antibody gene transfer, are briefly discussed. In addition to summarizing current principles of gene therapy for several groups of CNS disorders, the issues that remain to be resolved in clinical reality, such as delivery of the genetic material and regulation of the cellular expression of the transgene, and the negatives associated with the concepts of gene therapy, such as transient gene expression, toxicity of viral proteins, drawbacks of antisense therapy, and the problem of immune response to the transfected protein, have been also identified.
引用
收藏
页码:789 / 803
页数:15
相关论文
共 105 条
[1]   EXPRESSION AND MODULATION OF MAJOR HISTOCOMPATIBILITY ANTIGENS ON MURINE PRIMARY BRAIN-TUMOR INVITRO [J].
AKBASAK, A ;
OLDFIELD, EH ;
SARIS, SC .
JOURNAL OF NEUROSURGERY, 1991, 75 (06) :922-929
[2]   ATTENUATION OF STROKE SIZE IN RATS USING AN ADENOVIRAL VECTOR TO INDUCE OVEREXPRESSION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN BRAIN [J].
BETZ, AL ;
YANG, GY ;
DAVIDSON, BL .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1995, 15 (04) :547-551
[3]   IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY [J].
BI, WL ;
PARYSEK, LM ;
WARNICK, R ;
STAMBROOK, PJ .
HUMAN GENE THERAPY, 1993, 4 (06) :725-731
[4]   HUMAN GLIOBLASTOMA CELL DERIVED TRANSFORMING GROWTH-FACTOR-BETA-2 - EVIDENCE FOR SECRETION OF BOTH HIGH AND LOW-MOLECULAR-WEIGHT BIOLOGICALLY-ACTIVE FORMS [J].
BODMER, S ;
HUBER, D ;
HEID, I ;
FONTANA, A .
JOURNAL OF NEUROIMMUNOLOGY, 1991, 34 (01) :33-42
[5]   ICP34.5 MUTANTS OF HERPES-SIMPLEX VIRUS TYPE-1 STRAIN 17SYN+ ARE ATTENUATED FOR NEUROVIRULENCE IN MICE AND FOR REPLICATION IN CONFLUENT PRIMARY MOUSE EMBRYO CELL-CULTURES [J].
BOLOVAN, CA ;
SAWTELL, NM ;
THOMPSON, RL .
JOURNAL OF VIROLOGY, 1994, 68 (01) :48-55
[6]   A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].
BOUSSIF, O ;
LEZOUALCH, F ;
ZANTA, MA ;
MERGNY, MD ;
SCHERMAN, D ;
DEMENEIX, B ;
BEHR, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301
[7]  
BOVIATSIS EJ, 1994, CANCER RES, V54, P5745
[8]   GENE-THERAPY OF PARKINSON DISEASE-MODEL RAT BY DIRECT-INJECTION OF PLASMID DNA-LIPOFECTIN COMPLEX [J].
CAO, L ;
ZHENG, ZC ;
ZHAO, YC ;
JIANG, ZH ;
LIU, ZG ;
CHEN, SD ;
ZHOU, CF ;
LIU, XY .
HUMAN GENE THERAPY, 1995, 6 (11) :1497-1501
[9]  
CARMELIET P, 1995, THROMB HAEMOSTASIS, V74, P429
[10]   PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE [J].
CARMELIET, P ;
SCHOONJANS, L ;
KIECKENS, L ;
REAM, B ;
DEGEN, J ;
BRONSON, R ;
DEVOS, R ;
VANDENOORD, JJ ;
COLLEN, D ;
MULLIGAN, RC .
NATURE, 1994, 368 (6470) :419-424